RecruitingNCT06895291

Whole Body MRI in Oncology


Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Enrollment

1,000 participants

Start Date

Oct 26, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Multicenter, observational, prospective, study. All patients will be treated and monitored according to the local clinical practice. No additional procedures/patient visits in comparison with the usual clinical practice are planned for the study.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients candidate to WB-MRI according to clinical practice belonging to the study groups listed above.
  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged ≥ 18 years.
  • Life expectancy greater than 3 months.

Exclusion Criteria2

  • Patients with MRI-unsafe prostheses and devices.
  • Patients whose tests are of suboptimal quality, or whose test has been suspended, or is incomplete.

Interventions

DIAGNOSTIC_TESTWhole Body-Magnetic Resonance Imaging (WB-MRI)

This is a non-pharmacological, observational, prospective, study. Each patient will undergo quantitative WB-MRI as per clinical routine. WB-MRI may be performed: * at staging * at follow-up Disease progression is defined by clinicians taking into account all imaging modalities and clinicolaboratorial data available for the patients.


Locations(3)

IRCCS - Azienda Ospedaliero-Universitaria di Bologna - Policlinico di S. Orsola

Bologna, BO, Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.

Meldola, FC, Italy

IRCCS Istituto Europeo di Oncologia S.r.l.

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06895291


Related Trials